ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2049

Factor Structure and Convergent Validity of the Derriford Appearance Scale-24 Using Standard Scoring Versus Treating “Not Applicable” Responses As Missing Data: A Scleroderma Patient-Centered Intervention Network Cohort Study

Erin L. Merz1, Linda Kwakkenbos2,3,4, Marie-Eve Carrier2, Shadi Gholizadeh5, Sarah D. Mills6, Rina S. Fox7, Lisa Jewett2,8, Heidi Williamson9, Diana Harcourt9, Shervin Assassi10, Daniel E. Furst11, Karen Gottesman12, Maureen D Mayes13, Tim Moss9, Brett D. Thombs2,3 and Vanessa L. Malcarne6,14, 1Department of Psychology, California State University, Dominguez Hills, Carson, CA, 2McGill University, Montreal, QC, Canada, 3Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, 4Radboud University, Nijmegen, Netherlands, 5Psychoogy, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 6SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 7Northwestern University Feinberg School of Medicine, Chicago, IL, 8Jewish General Hospital, Montreal, QC, Canada, 9University of the West of England, Bristol, United Kingdom, 10University of Texas McGovern Medical School, Houston, TX, 11Department of Internal Medicine and Rheumarology, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology; University of Washington, Seattlr, Washington; University of Florence, Florence, Italy, Los Angeles, CA, 12Scleroderma Foundation, Los Angeles, CA, 13Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 14Psychology, San Diego State University, San Diego, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: ARHP Measures and Measurement of Healthcare Quality Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Valid measures of appearance concern are needed in systemic sclerosis, a rare, disfiguring rheumatologic disease. The Derriford Appearance Scale-24 (DAS-24) is a self-report measure that assesses appearance-related distress related to visible differences. There is uncertainty regarding the DAS-24 factor structure, possibly due to its scoring method of the 14 items with a “not applicable” response option.

Methods: Patients with systemic sclerosis (N = 950) completed self-report measures at enrollment to the Scleroderma Patient-centered Intervention Network (SPIN) Cohort Study. DAS-24 items marked “not applicable” were scored two ways: (1) “not applicable” scored as 0, per standard DAS-24 scoring; (2) “not applicable” treated as missing. Internal consistency reliability was evaluated using Cronbach’s alpha. The one-factor DAS-24 model was evaluated using confirmatory factor analysis. Convergent validity was evaluated using bivariate correlations with social interaction anxiety, depressive symptomatology, fear of negative evaluation, and satisfaction with appearance.

Results: Internal consistency reliability was high (α = .92). When items marked by respondents as “not applicable” were scored as 0, the one-factor model fit poorly (CFI = .896, RMSEA = .096). When items marked by respondents as “not applicable” were treated as missing data, the one-factor model fit well (CFI = .958, RMSEA = .065). Convergent validity analyses revealed strong correlations that were similar across scoring methods (Standard rs: .44-.68; Missing rs: .47-.72).

Conclusion: Treating “not applicable” responses as missing improved the measurement model, but did not yield substantively different relationships with theoretically related constructs. It is unlikely that using standard DAS-24 scoring greatly impacts the practical interpretation of scores. Indications of item redundancy and poorly performing items suggest that the DAS-24 could be improved and potentially shortened.


Disclosure: E. L. Merz, None; L. Kwakkenbos, None; M. E. Carrier, None; S. Gholizadeh, None; S. D. Mills, None; R. S. Fox, None; L. Jewett, None; H. Williamson, None; D. Harcourt, None; S. Assassi, None; D. E. Furst, None; K. Gottesman, None; M. D. Mayes, None; T. Moss, Derriford Appearance Scale, 4; B. D. Thombs, None; V. L. Malcarne, None.

To cite this abstract in AMA style:

Merz EL, Kwakkenbos L, Carrier ME, Gholizadeh S, Mills SD, Fox RS, Jewett L, Williamson H, Harcourt D, Assassi S, Furst DE, Gottesman K, Mayes MD, Moss T, Thombs BD, Malcarne VL. Factor Structure and Convergent Validity of the Derriford Appearance Scale-24 Using Standard Scoring Versus Treating “Not Applicable” Responses As Missing Data: A Scleroderma Patient-Centered Intervention Network Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/factor-structure-and-convergent-validity-of-the-derriford-appearance-scale-24-using-standard-scoring-versus-treating-not-applicable-responses-as-missing-data-a-scleroderma-patient-c/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factor-structure-and-convergent-validity-of-the-derriford-appearance-scale-24-using-standard-scoring-versus-treating-not-applicable-responses-as-missing-data-a-scleroderma-patient-c/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology